US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024

We Like The Quality Of Edwards Lifesciences' (NYSE:EW) Earnings

Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insight

Edwards Lifesciences Corporation (EW) Fell Due to Missed Earnings Expectations and Weak Guidance

Edwards, Medtronic and Inari share trial data at TCT conference

Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation

TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

JPMorgan views Edwards Lifesciences TAVR data positively

Bernstein Lifts Edwards Lifesciences Rating, Sees Balanced Risk-Reward in Tavr Market

Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

International Markets and Edwards Lifesciences (EW): A Deep Dive for Investors

Edwards Lifesciences price target raised to $85 from $80 at Barclays